IONIS PHARMACEUTICALS INC

IONS stock represents ownership in Ionis Pharmaceuticals, Inc., a biotechnology company focused on developing RNA-targeted therapies. The ticker IONS trades on the Nasdaq Global Select Market. As a stock, it gives investors a stake in the company's drug discovery and development efforts, which target a range of diseases. The company generates revenue through partnerships, royalties, and its own commercial products. IONS is not a diversified healthcare fund; it is a single-company equity tied to the success of its pipeline and collaborations.

The 52-week range shows the lowest and highest prices at which IONS shares have traded over the past year. It helps investors gauge recent price volatility and where the current price sits relative to that span. Because the range changes daily, check the latest IONS quote on this page for the most current 52-week high and low. Comparing the current price to that range can provide context for recent performance.

Recent performance for IONS depends on a mix of company-specific news, clinical trial updates, partnership announcements, and broader market conditions. For the latest price changes over various periods, refer to the performance data displayed on this page, which typically includes daily, weekly, monthly, and year-to-date returns. Because Ionis operates in the volatile biotech sector, short-term moves can be significant. Reviewing both short- and long-term trends provides a more complete picture.

Valuing IONS often involves more than traditional metrics like the price-to-earnings ratio because biotech companies may have uneven earnings due to research and development cycles. Investors may look at price-to-sales, price-to-book, cash flow, and pipeline potential. Comparing IONS to peers in the biotechnology industry can also be useful. For current valuation ratios, consult the latest data on this page, as these figures change with the stock price and financial reports.

Key risks for IONS include clinical trial failures, regulatory setbacks, reliance on partnerships, competition in the RNA-targeted therapeutics space, and intellectual property challenges. Because the company invests heavily in research and development, negative trial results or delays can significantly impact the stock. Additionally, broader biotech sector sentiment, interest rate changes, and reimbursement policies may affect performance. Investors should review Ionis's annual reports and pipeline updates to understand these risks.

Important metrics for IONS include revenue growth, net income or loss, operating expenses, cash and equivalents, and research and development spending. Because Ionis often reports milestone payments and royalty revenues, analyzing the consistency of these streams is useful. Investors may also track the number of drugs in late-stage trials and partnership agreements. For exact figures, refer to Ionis's quarterly and annual financial statements filed with the SEC or summarized on this page.